A review of nelfinavir for the treatment of HIV infection

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 2, 2006, Pages 285-300

  Olmo, Montserrat ^a   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

HIV infection; Nelfinavir; Protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; METHADONE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

DOSE RESPONSE; DRUG ANTAGONISM; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; PREGNANCY; REVIEW; VIRUS RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; FEMALE; PREGNANCY COMPLICATION; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

FEMALE; HIV INFECTIONS; HUMANS; MOLECULAR STRUCTURE; NELFINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 33847760369     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.2.285     Document Type: Review

References (114)

1. PALELLA FJ Jr, DELANEY K, MOORMAN A et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. (1998) 338(13):853-860.
2. VIRACEPT® nelfinavir mesylate: product labelling. Agouron Pharmaceuticals, Inc., La Jolla, CA, USA (2004).
3. GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-1-INFECTED ADULTS AND ADOLESCENTS: Developed by the Pannel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) (2005).
4. BARDSLEY-ELLIOT A, POLSKER GL: Nelfinavir. An update on its use in HIV infection. Drugs (2000) 59(3):581-620. Extensive update on NFV pharmacology, clinical efficacy and tolerability.
5. PATICK A, BORITZIT, BLOOM LA: Activities of the HIV-1 protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. (1997) 41:2159-2164.
6. PAI VB, NAHATA MC: Nelfinavir mesylate: a protease inhibitor. Ann. Pharmacother. (1999) 33:325-339.
7. SPECK R, FLEXNER C, YU XF: Accumulation of gag-pol polyprotein intermediates in HIV-infected cells treated with protease inhibitors (abstract no. 184). 12th World AIDS Conference. Geneva, Switzerland (1998).
8. FORD J, CORNFORTH D, HOGGARD PG et al.: Intracellular and plasma pharmacokinetics or nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir. Ther. (2004) 9(1):77-84.
9. POIRIER JM, ROBIDOU P, JAILLON P: Simple and simultaneous determination of the HIV-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus MS nelfinavir metabolite and the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. Ther. Drug Monit. (2005) 27(2):186-192.
10. KAPPELHOFF BS, CROMMENTUYN KML, DEMAAT MMR et al.: Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. (2004) 43(13):845-853.
11. DUVAL X, PEYTAVIN G, ALBERT I et al.: Determination of indinavir and nelfinavir trough plasma concentration efficacy thersholds according to virological response in HIV-infected patients. HIV Med. (2004) 5(4):307-313.
12. PELLEGRIN I, BREILH D, MONTESTRUC F et al.: Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS (2002) 16:1331-1340.
13. LE MOING V, PEYTAVIN G, JOURNOT V et al.: Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients. J. Acquir. Immune Defic. Syndr. (2003) 34(5):497-499.
14. BURGER DM, HUGEN PW, AARNOUTSE RE et al.: Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther. Drug Monit. (2003) 25(1):73-80.
15. CASADO JL, MORENO S, HERTOGS K et al.: The NELSANE Study. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS (2002) 16:47-52.
16. JUSTESEN US, HANSEN IM, ANDERSEN AB et al.: The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1250 mg twice-daily regimen in HIV-infected patients. HIV Med. (2005) 6(5):334-340.
17. HAAS D, CLOUGH L, JOHNSON B et al.: Quantification of nelfinavir (NFV) and its active metabolite (M8) in CSF and plasma, and correlation with CSF HIV-1 RNA response (abstract no. 313). 7th Conference on Retroviruses and Oportunistic Infections. San Francisco, CA, USA (2000).
18. SOLAS C, LAFEUILLADE A, HALFON P et al.: Discrepancies betwen protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2003) 47(1):238-243.
19. PODZAMCZER D, FERRER E, CONSIGLIO E et al.: A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naïve patients (the Combine Study). Antivir. Ther. (2002) 7(2):81-90. First trial comparing NFV with an NNRTI.
20. ZORILLA C, CURRIER J, CLARK et al.: Cervicovaginal HIV RNA in HIV-positive women on 48 weeks of dual protease inhibitor combination therapy (abstract no. 233/oral presentation). 7th European Conference on Clinical Aspects and Treatment of HIV. Lisbon, Portugal (1999).
21. ZHANG K, WU E, PATICK et al.: Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: quantification by LC-MS/MS and antiviral activities (abstract no. 128). 6th European ISSX Meeting. Gothenburg, Sweden (1997).
22. SHETTY BV, KOSA MB, KHALIL DA et al.: Preclinical pharmacokinetics and distribution to tissue of AG-1343, an inhibitor of human immunodeficiency virus type I protease. Antimicrob. Agents Chemother. (1996) 40:110-114.
23. AWEEKA F, MOTOYA T, THEVANAYAGAML et al.: Nelfinavir unbound drug interactions and protein binding characteristics (abstract 448-W). 9th Conference on Retroviruses and Oportunistic Infections. Seattle, WA, USA (2002).
24. DE BETHUNE MP, XIE D, AZJIN H et al.: Influence of binding to human plasma proteins by protease inhibitors may be overestimated in current IQ models (abstract 449-W). 9th Conference on Retroviruses and Oportunistic Infections. Seattle, WA, USA (2002).
25. REGAZZI MB, SEMINARI E, VILLANI P et al.: Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile. J. Chemother. (2001) 13(5):569-574.
26. HSYU P, PETERSEN C, PUN E, DANIELS E: Increased bioavailability of nelfinavir 625 mg tablet and the potential impact on adverse experiences. [Antivir. Ther. (2003) 8:L77]. 5th International Workshop on adverse drug reactions and lipodystrophy in HIV. Paris, France (2003).
27. MARZOLINI C, BUCLIN T, DECOSTERD LA, BIOLLAZ J, TELENTI A: Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther. Drug Monit. (2001) 23(4):394-398.
28. HIRANI VN, RAUCY JL, LASKER JM: Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab. Dispos. (2004) 32(12):1462-1467.
29. MOYLE GI, BACK D: Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. (2001) 2:105-113.
30. PETERSEN C, PUN E, STRADA R, DANIELS E, BRAMSON C, RANDINITIS E: Pharmacokinetics of nelfinavir (viracept 250 mg tablests): effect of food intake on single-dose PK parameters (abstract 544). 10th Conference on Retroviruses and Oportunistic Infections. Boston, MA, USA (2003).
31. KUROWSKY M, KAESER B, SAWYER A et al.: Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily. Eur. J. Med. Res. (2002) 7(10):453-456.
32. KAESER B, CHAROIN JE, GERBER M et al.: Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. Int. J. Clin. Pharmacol. Ther. (2005) 43(3):154-162. Study to confirm bioequivalence of both tablet formulations.
33. AARNOUTSE R, BURGER D, VAN OOSTERHOUT J et al.: Influence of food on the pharmacokinetics (PK) of once daily (OD) nelfinavir (NFV)/ritonavir (RTV) combinations in healthy volunteers (abstract 346). 1st International AIDS Society on HIV pathogenesis and Treatment. Buenos Aires, Argentina (2001).
34. VON MOLTKE LL, GREENBLATT DJ, GRASSI JM et al.: Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. (1998) 38:106-111.
35. JACKSON KA, ROSENBAUM SE, YUEN G et al.: Population pharmacokinetic analysis of Viracept™ (nelfinavir mesylate) in HIV-1 infected patients enrolled in a Phase III clinical trial (abstract no. 42267). 12th World AIDS Conference. Geneva, Switzerland (1998).
36. SHARMA R, BELLANTONE B, SINGH D: A comparison of the pharmacokinetics of nelfinavir in African-American women versus men with HIV infection (abstract no. WePeB5970, poster exhibition). XIV International AIDS Conference. Barcelona, Spain (2002).
37. KHALIQ Y, GALLICANO K, SEGUIN I et al.: Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br. J. Clin. Pharmacol. (2000) 50(2):108-115.
38. REGAZZI M, MASERATI R, VILLANI P et al.: Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus-positive and HIV-Hepatitic C virus-coinfected subjects. Antimicrob. Agents Chemother. (2005) 49(2):643-649. Differences in NFV PK between HCV-co-infected and non-co-infected patients.
39. WALMSLEY S, BERNSTEIN B, KING M et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. (2002) 364(26):2039-2046. Comparison of nelfinavir with LPV-RTV in naïve patients in terms of efficacy and tolerance.
40. SULKOWSKY MS, MEHTA SH, CHAISSON RE, THOMAS DL, MOORE RD: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 18:2277-2284. Protease inhibitors-related hepatotoxicity.
41. MURPHY RL, SANNE I, CAHN P et al.: Dose-ranging randomized clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48 weeks results. AIDS (2003) 17:2603-2614.
42. SHERMAN KE, SHIRE NJ, CERNOHOUS P et al.: Evaluation of HCV RNA and liver injury in HCV/HIV co-infected patients initiating lopinavir/r or nelfinavir-based therapy (abstract 811). 11th Conference on Retroviruses and Oportunistic Infections. San Francisco, CA, USA (2004).
43. IZZEDINE H, DIQUET B, LAUNAY-VACHER V: Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency. AIDS (1999) 13:1989.
44. ARMBRUSTER C, VORBACH H, El MENYAWI I, MEISL FT, NEUMANN I: Pharmacokinetics of nelfinavir during hemodialysis in a pacient with HIV infection. AIDS (2000) 14(1):99-101.
45. TAYLOR S, LITTLE J, HALIFAX K, DRAKE S, BACK D: Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis. J. Antimicrob. Chemother. (2000) 45:716-717.
46. VAN HEESWIJK RP, SCHERPIBIER HJ, DE KONING LA et al.: The pharmacokinetics of nelfinavir in HIV infected children. Ther. Drug Monit. (2002) 24(4):487-491.
47. LITALIEN C, FAYE A, COMPAGNUCCI A et al.: Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr. Infect. Dis. J. (2003) 22(1):48-55.
48. BERGSHOEFF AS, FRAAIJ PL, VAN ROSSUM AM et al.: Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir. Ther. (2003) 8(3):215-222.
49. FLOREN LC, WIZNIA A, HAYASHI S et al.: Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics (2003) 112(3 Pt 1):669-670.
50. PAYEN S, FAYE A, COMPAGNUCCI A et al.: Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immnunodeficiency virus type 1. Antimicrob. Agents Chemother. (2005) 49(2):525-535.
51. GATTI G, CASTELLI-GATTINARA G, CRUCIANI G et al.: Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin. Infect. Dis. (2003) 36(11):1476-1482.
52. BURGER DM, BERGSHOEFF AS, DE GROOT R et al.: Maintaining the nelfinavir trough concentration above 0.8 mg/l improves virologic response in HIV-1 infected children. J. Pediatr. (2004) 145(3):403-405. Particular NFV PK in children and its importance in virological success.
53. SAITOH A, SINGH KK, POWELL CA et al.: An MDRI-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS (2005) 19(4):371-380.
54. ABOULKER JP, BABIKER A, COMPAGNUCCI A et al.: Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet (2002):733-740.
55. PEYTAVIN G, WROBEL C, CAMUS M et al.: Placental transfer of nelfinavir studied in the human in vitro placental perfusion model. (abstract 769). 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina (2001).
56. COVINGTON DL, CONNER SD, DOI PA, SWINSON J, DANIELS EM: Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet. Gynecol. (2004) 103(6):1181-1189.
57. MARQUES R, SILVA S, FERREIRA A, PIÑEIRO C, SENAO R: Prevention of mother to child transmission of HIV-1 with antiretroviral regimens containing nelfinavir (abstract Th PeB7099). XV International AIDS Conference. Bangkok, Thailand (2004).
58. TIMMERMANS S, TEMPELMAN C, GODFRIED MH et al.: Nelfinavir and nevirapine side effects during pregnancy. AIDS (2005) 19(8):795-799.
59. VAN HEESWIJK RP, KHALIQ Y, GALLICANO KD et al.: The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin. Pharmacol. Ther. (2004) 76(6):588-597. Particular NFV PK during pregnancy.
60. BRYSON J, STEK A, MIROCNICK M et al.: Pharmacokinetics, antiviral activity and safety of nelfinavir with zidovudine/lamivudine in pregnant HIV-infected women and their infants. PACTG 353 cohort 2 (abstract 795w). 9th Conference on Retroviruses and Oportunistic Infections. Seattle, WA, USA (2002).
61. NELLEN JF, SCHILLEVOORT I, WIT FW et al.: Nelfinavir plasma concentrations are low during pregnancy. Clin. Infect. Dis. (2004) 39(5):736-740. Particular NFV PK during pregnancy.
62. CASADO A, BADIA X, CONSIGLIO E et al.: Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE QoL substudy). HIV Clin. Trials (2004) 5(3):132-140.
63. ROCA B, GOMEZ CJ, ARNEDO A: A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients. AIDS (2000) 14:157-161.
64. PEREZ G, MACARTHUR RD, WALMSLEYS, BAXTER JA, MULLIN C, NEATON JD: A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clin. Trials (2004) 5(1):7-18.
65. ANDRADE A, SEARS C, RUFO O, LENCER W, FLEXNER C: Characterization of nelfinavir (NFV)-associated diarrhea: secretory versus osmotic (abstract 62). 7th Conference on Retroviruses and Oportunistic Infections. San Francisco, CA, USA (2000).
66. HSYU PH, FLEXNER C, CHU A, PETERSEN C: Correlation of efficacy, nelfinavir pharmacokinetics and diarrhea in treatment-naïve HIV-positive patients recieving nelfinavir, zidovudine and lamivudine (abstract I-1735). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001).
67. GUEST JL, RUFFIN C, TSCHAMPA JM, DESILVA KE, RIMLAND D: Differences in rates of diarrhea in patients with human immunodeficieny virus receiving lopinavir-ritonavir or nelfinavir. Pharmacotherapy (2004) 24(6):727-735.
68. RODRIGUEZ-FRENCH A, BOGHOSSIAN J, GRAY GE et al.: The NEAT Study: a 48-week open-label study to compare the antiviral efficacy and safety of GW-433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1 infected patients. J. Acquir. Immune Defic. Syndr. (2004) 35(1):22-32.
69. GATHE JC Jr, IVE P, WOOD R et al.: SOLO: 48-weeks efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1 infected patients. AIDS (2004) 18(10:15298-15337.
70. RACHLIS A, GILL MJ, BARIL JG et al.: Step-wise intervention for the management of nelfinavir (NFV)-associated diarrhea (abstract 747). 2nd International AIDS Society on HIV Pathogenesis and Treatment. Paris, France (2003).
71. JOHNSON M, NIETO CISNEROS L, HORBAN A et al.: Comparison of gastrointestinal tolerability and patient preference for treatment with the 625-mg and 250-mg nelfinavir tablet formulations. HIV Med. (2005) 6(2):107-113.
72. MATHERON S, DESCAMPS D, BOUE F et al.: Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/ nelfinavir as first-line therapy in HIV-1 infected adults: a randomized trial. Antivir. Ther. (2003) 8(2):163-171.
73. JOLY V, GERBE J, DRISS F et al.: Lipid profile alterations induced by three different PI containing regimens (nelfinavir, lopinavir/ritonavir and indinavir/ritonavir) in a cohort of HIV-infected patients (abstract 711). 2nd International AIDS Society on HIV Pathogenesis and Treatment. Paris, France (2003).
74. TRELUYER JM, MORINI JP, DIMET J et al.: High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeciency virus-infected patients. Antimicrob. Agents Chemother. (2002) 46(12):4009-4012.
75. MARTINEZ E, VICIANA P, PULIDO, GONZALEZ J, LABARGA P, DOMINGO P: The introduction of nelfinavir-containing antiretroviral therapy does not increase the estimated cardiovascular risk at 6 months in HIV- infected adults (abstract WePeB5940). XV International AIDS Conference. Bangkok, Thailand (2004).
76. DUBE M, ZACKIN R, PARKER R et al.: Prospective study of glucose and lipid metabolism in antiretroviral-naive subjects randomized to receive nelfinavir, efavirenz or both combined with zidovudine + lamivudine or didanosine + stavudine: A5005s, a substudy of ACTG 348 (abstract 74). 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004).
77. FISAC C, VIRGILI N, FERRER E et al.: A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J. Clin. Endocrinol. Metab. (2003) 88(11):5186-5192. Report of some data supporting a better lipidic profile of NFV if compared with other PIs.
78. VINCENT S, TOURNIAIRE F, El YAZIDI et al.: Nelfinavir induces necrosis of 3T3F44-2 adipocytes by oxidative stress. J. Acquir. Immune Defic. Syndr. (2004) 37(5):1556-1562.
79. DOWELL P, LANE MD: C/EBPα reverses the antiadipogenic effects of the HIV protease inhibitor nelfinavir. Biochem. Biophys. Res. Commun. (2005) 327:571-574.
80. BEN-ROMANO R, RUDICH A, TIROSH A et al.: Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-ζ. Diabetologia (2004) 47(6):1107-1117.
81. MEHTA S, MOORE R, THOMAS D, CHAISSON RE, SULKOWSKY M: The effect of HAART and HCV infection on the development of diabetes mellitus (abstract 679-T). 9th Conference on Retroviruses and Oportunisttc Infections. Seattle, WA, USA (2002).
82. NOLAN D, UPTON R, NCKINNON E et al.: Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS (2001) 15(10):1275-1280.
83. HEWITT RG, THOMSON WM, CHU A, HERNANDEZ F, SHELTON M: Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy (abstract 658). 8th Conference on Retroviruses and Oportunistic Infections. Chicago, IL, USA (2001).
84. SENSION M, ELION R, FARTHING C et al.: Open label pilot studies to asses the safety of b.i.d. dosing regimens of viracept (nelfinavir mesylate) combined with NRTI's in HIV-infected treatment-naive patients (abstract 387a). 5th Conference on Retroviruses and Oportunistic Infections. Chicago, IL, USA (1998).
85. SAAG MS, TEBAS P, SENSION M et al.: Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS (2001) 15:1971-1978.
86. GARTLAND M; AVANTI STUDY GROUP: AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1 infected antiretroviral-naive patients. Antivir. Ther. (2001) 6(2):127-134.
87. JOHNSON M, PETERSEN A, WINSLADE J, CLENDENINN N: Comparison of BID and TID dosing of viracept (nelfinavir) in combination with stavudine (d4T) and lamivudine (3TC) (abstract 373). 5th Conference on Retroviruses and Oportunistic Infections. Chicago, IL, USA (1998).
88. RUIZ I, KNOBEL H, GONZALEZ J et al.: A comparison of the long-term antiviral efficacy and compliance of twice daily (BID) and three times daily (TID) dosing of nelfinavir in a HIV cohort (abstract 225). 1st International AIDS Society on HIV Pathogenesis and Treatment. Buenos Aires, Argentina (2001).
89. QUIROS-ROLDAN E, MORETTI F, TORTI C et al.: HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens. J. Clin. Lab. Analysis (2005) 19:26-29.
90. KUROWSKY M, KAESER B, SAWYER A, POPESCU M, MROZIKIEWICZ A: Low-dose ritonavir moderately enhances nelfinavir exposure. Clin. Pharmacol. Ther. (2002) 72(2):123-132.
91. STOCKER H: Pharmacokinetic interaction between saquinavir/r and nelfinavir in HIV-infected patients (abstract A-454). 4th Interscience Conference on Antimicrob Agents and Chemotherapy. Washington, DC, USA (2004).
92. PFISTER M, LABBE L, LU JF et al.: Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin. Pharmacol. Ther. (2002) 72(2):133-141.
93. KLEIN C, BERTZ R, ASHBRENNER E et al.: Assessment of the multiple-dose pharmacokinetic interaction of lopinavir/ritonavir with nelfinavir (abstract 536). 10th Conference on Retroviruses and Oportunistic Infections. Boston, MA, USA (2003).
94. DICENZO R, FORREST A, FISCHL MA et al.: Pharmacokinetics of indinavir and nelfinavir in treatment-naïve, human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. (2004) 48(3):918-923.
95. VILARO J, MASCARO J, COLOMER J, CUCURULL J, GARCIA D, YAÑEZ A: The pharmacokinetics of combination therapy with (NFV) plus nevirapine (NVP) in HIV-positive patients (abstract A-497). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001).
96. LA PORTE CJ, DE GRAAFF-TEULEN MJ, COLBERS EP et al.: Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. Br. J. Clin. Pharmacol. (2004) 58(6):632-640.
97. PFISTER M, LABBE L, HAMMER SM et al.: Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. (2003) 47(1):130-137.
98. KRUSE G, ESSER S, STOCKER H et al.: The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Antivir. Ther. (2005) 10(2):349-355.
99. SHELTON MJ, CLOEN D, BECKER M, HSYU PH, WILTON JH, HEWITT RG: Evaluation of the pharmacokinetic (PK) interaction between phenytoin (Phen) and nelfinavir (NFV) in healthy volunteers at steady state (abstract 426). 40th Interscience Conference of Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada (2000).
100. ANTONIOU T, TSENG AL: Interactions between recreational drugs and antiretroviral agents. Ann. Pharmacother. (2002) 36(10):1598-1613.
101. BROWN LS, CHU M, AUG C, DABO S: The use of nelfinavir and two nuleosides concomitantly with methadone is effective and well-tolerated in HepC co-infected patients (abstract I-206). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001).
102. BRATT G, STAHLE L: Sildenafil does not alter nelfinavir pharmacokinetics. Ther. Drug Monit. (2003) 25(2):240-242.
103. JACKSON KA, ROSENBAUM SE, KERR BM, PITHAVALA YK, YUEU G, DUDLEY MN: A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a Phase III clinical trial. Antimicrob. Agents Chemother. (2000) 44(7):1832-1837.
104. STONE JA, MIGOYA E, HICKLEY L et al.: Drug interactions between caspofungin and nelfinavir or rifampin (abstract A-1605). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
105. AMSDEN GW, NAFZINGER AN, FOULDS G, CABELUS LF: A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J. Clin. Pharmacol. (2000) 40(12 Pt 2):1522-1527.
106. GERBER JG, ROSENKRANZ S, FICHTENBAUM CJ et al.: The effect of efavirenz (EFV) and nelfinavir (NFV) on the pharmacokinetis (PK) of pravastatin (P) (abstract 870). 2nd International AIDS Society on HIV Pathogenesis and Treatment. Paris, France (2003).
107. SCHVARCZ R, RUDBECK G, SODERDAHL G, STAHLE L: Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation (2000) 69(10):2194-2195.
108. JAIN AK, VENKATARAMANAN R, FRIDELL JA et al.: Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. (2002) 8(9):838-840.
109. PARK-WYLLIE LY, ANTONIOU T: Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS (2003) 17(4):638-640.
110. HSYU PH, SCHULTZ-SMITH MD, LILLIBRIDGE JH, LEWIS RH, KERR BM: Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob. Agents Chemother. (2001) 45(12):3445-3450.
111. HARE CB, VU MP, GRUNFELD C, LAMPIRIS HW: Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin. Infect. Dis. (2002) 35(10):e111-e112.
112. BERGSHOEFF AS, WOFS TF, GEELEN SP, BURGER DM: Ritonavir enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. Ann. Pharmacother. (2003) 37(4):521-525.
113. http://aidsinfo.nih.gov Guidelines for the use of antiretroviral agents in pediatric HIV infection (2005).
114. http://aidsinfo.nih.gov Antiretroviral post-exposure prophilaxis after sexual intercourse, injection-drug abuse or other nonoccupational exposure to HIV in the US. Recommendations from the US Department of Health and Human Services.